Following an application from Cambridge Theranostics Ltd., submitted pursuant to Article 14(1)(a) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of Lycopene-whey complex on risk of atherosclerotic plaques (Question No EFSA-Q-2008-703) [The EFSA Journal (2009) 1179, 1-10.]. The claim proposed by the applicant was worded as follows: ‘Lycopene-whey complex prevents oxidative damage of plasma lipoproteins, which reduces the build up of arterial plaques and reduces the risk of heart disease, stroke and other clinical complications of atherosclerosis’.
Recital 12, Commission Regulation (EU) No 384/2010 of 5 May 2010 on the authorisation and refusal of…
In forcesince 5 May 2010